Research for treatments, prevention and a cure
Page template: single-clinical-trials.php
Search terms : 

Clinical Trials

  • Clinical Studies

General (uncategorized) trials (GEN)

TMC125 Expanded access programme

Early access of TMC125 in combination with other antiretrovirals in treatment-experienced HIV-1 infected subjects with limited treatment options (TMC125-C214) This...
Print Friendly, PDF & Email

Early access of TMC125 in combination with other antiretrovirals in treatment-experienced HIV-1 infected subjects with limited treatment options (TMC125-C214)

This trial is also listed on

Update:This treatment has now been approved for sale to the public.

About the study

The purpose of this study is to provide early access to TMC125 for HIV-1 infected patients who have been on multiple failing antiretroviral (ARV) regimens and have limited treatment options with currently approved ARVs. Information on safety and tolerability aspects of TMC125 in combination with other ARVs in treatment-experienced HIV-1 patients with limited treatment options will be assessed. Available data regarding the effectiveness of the drug will also be collected.

All participants will receive TMC125 in the form of two 100 mg tablets to be taken orally following a meal every 12 hours. TMC125 will be administered in combination with an investigator-selected background of additional ARVs from the list of allowed medications. Study treatment will be continued until virologic failure, treatment-limiting toxicity, patient lost to follow-up, withdrawal, or pregnancy.

TMC125 will be provided via the expanded access program until discontinuation of TMC125 development or when TMC125 becomes commercially available in Canada.

About the treatment/intervention

TMC125 is an experimental non-nucleoside reverse transcriptase inhibitor (NNRTI) being developed by Tibotec.


Eligibility criteria


  • Patient is at least 3-class experienced (3 classes of licensed oral antiretrovirals: nucleoside/tide reverse transcriptase inhibitors [N[t]RTI], protease inhibitors [PI], non-nucleoside reverse transcriptase inhibitors [NNRTI])
  • Patients with primary NNRTI resistance can be included if they are experienced with at least 2 classes of ARVs (PIs, N[t]RTIs) and meet all the other inclusion criteria Patient has previously received 2 different PI-based regimens
  • Patient is unable to use currently approved NNRTIs due to resistance (primary or acquired) and/or intolerance
  • Patient, if currently receiving an ARV regimen, is not achieving adequate virologic suppression on his/her current regimen


  • Prior or current participation in DUET trials (TMC125-C206 or TMC125-C216)
  • Use of disallowed concomitant therapy, including disallowed antiretrovirals (ARV)
  • Use of investigational ARVs (with exceptions)
  • Any active clinically significant disease (e.g., cardiac dysfunction, pancreatitis, acute viral infection) or findings during screening of medical history or physical examination that is not either resolved or stabilized for at least 30 days before the screening phase
  • Pregnant or breast-feeding female
  • Female patient of childbearing potential not using effective non-hormonal birth control methods
  • Patients with specific laboratory abnormalities
  • Patients with clinical or laboratory evidence of significantly decreased hepatic function or decompensation

Note: Other criteria may apply.

Participating sites

If you are interested in taking part in this trial, speak to your doctor or contact the following study site directly:


Southern Alberta HIV Clinic, Calgary, AB
Dr. John Gill

University of Alberta Hospital, Edmonton, AB
Dr. Stephen Shafran

British Columbia

St. Paul’s Hospital, Vancouver, BC
Dr. Julio Montaner

Downtown IDC, Vancouver, BC
Dr. Brian Conway


Heath Sciences Centre, Winnipeg, MB
Dr. Ken Kasper


Ottawa General Hospital – General Campus, Ottawa, ON
Dr. Jonathan Angel

University of Ottawa Health Services, Ottawa, ON
Dr. Donald Kilby

Hamilton Health Sciences Centre, Hamilton, ON
Dr. Fiona Smaill
905-521-9800 ext. 76307

Sunnybrook, Toronto, ON
Dr. Anita Rachlis

Maple Leaf Medical Clinic, Toronto, ON
Dr. Mona Loutfy

Danforth Clinic, Toronto, ON
Dr. Gary Rubin

Toronto General Hospital, Toronto, ON
Dr. Sharon Walmsley

St. Clair Medical Association, Toronto, ON
Dr. Ken Logue

Positive Care Clinic/Lakeridge Health, Whitby, ON
Dr. Michael Silverman

St. Michael’s Hospital, Toronto, ON
Dr. Kevin Gough
416-864-6060 ext. 5668

Tsang Medicine Medical Corporation, Toronto, ON
Dr. Albert Tsang

Windsor Regional Hospital – Metropolitan Campus, Windsor, ON
Dr. Corinna Quan

Lawson Health Research Institute, London, ON
Dr. Edward Ralph

Kingston General Hospital, Kingston, ON
Dr. Wendy Wobeser


Montreal General Hospital, Montreal, QC
Dr. Chris Tsoukas

Montreal Chest/Royal-Victoria, Montreal, QC
Dr. Norbert Gilmore
514-934-1934 ext. 32144

Clinique Médicale l’Actuel, Montreal, QC
Dr. Benoît Trottier

Clinique du Quartier Latin, Montreal, QC
Dr. Patrice Junod

CHUM – Notre-Dame Hospital, Montreal, QC
Dr. Danielle Rouleau
514-890-8000 ext. 24720

Centre hospitalier de Québec-Pavillon CHUL, Ste. Foy, QC
Dr. Sylvie Trottier

New Brunswick

Moncton Hospital, Moncton, NB
Dr. Gordon Dow

Latest News

This is our community: World AIDS Day 2018

| Uncategorized | No Comments

Bridging the Gap: Community and researchers allied in fight to end HIV There is a line in Tony Kushner’s 1991…

CTN at AIDS 2018

| Uncategorized | No Comments

The 22nd International AIDS Conference (AIDS 2018) is the premier gathering for individuals working in the field of HIV, policy makers,…

CTNPT 031 — The HAVARTI trial

| Uncategorized | No Comments

“Our study will test whether a licensed and commonly used medication could lead to a functional cure for HIV infection,”…

CTN at CAHR 2018

| Uncategorized | No Comments

Along with supporting CAHR as a Bronze Sponsor, the CTN is proud to host several important events throughout the week.

Research for treatments, prevention and a cure